Medicamen Biotech

Medicamen Biotech Net Margin

The Net Profit Margin of Medicamen Biotech (MEDICAMEQ.NS) as of Oct 19, 2026 is 4.88 %. In the previous year, Net Profit Margin was 4.37 % — a change of 11.48% (higher).

Net Margin

4.88 %

YoY

11.48%

Last updated:

Net Profit Margin of Medicamen Biotech is 2026 4.88 % . Net Profit Margin of Medicamen Biotech was 2025 4.37 % . It decreases by 11.48% higher compared to the previous year.

Medicamen Biotech's net margin stands at 4.9%, down from 12.9% several years earlier.

The Medicamen Biotech Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2019
9.81 INR
Jan 1, 2020
10.59 INR
Jan 1, 2021
10.76 INR
Jan 1, 2022
12.90 INR
Jan 1, 2023
10.54 INR
Jan 1, 2024
6.10 INR
Jan 1, 2025
4.37 INR
Jan 1, 2026
4.88 INR
The Medicamen Biotech Net Margin history
YEARNet MarginYoY
4.88 %+11.48%
4.37 %-28.27%
6.10 %-42.15%
10.54 %-18.34%
12.90 %+19.92%
10.76 %+1.61%
10.59 %+7.97%
9.81 %+8.15%
9.07 %+44.92%
6.26 %+775.48%
0.71 %+26.20%
0.57 %+340.52%
0.13 %-266.99%
-0.08 %+838.75%
-0.01 %-136.32%
0.02 %-42.29%
0.04 %+145.29%
0.02 %-18.72%
0.02 %-21.77%
0.03 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Medicamen Biotech Stock analysis

What does Medicamen Biotech do? Medicamen Biotech Ltd, based in New Delhi, India, operates in the Health Care sector, specifically within Pharmaceuticals. The company manufactures and markets diverse pharmaceutical formulations, including oral solids, liquids, ointments, and injectables for both non-oncology and oncology treatments. It focuses on oncology therapeutics, cardiology, central nervous system disorders, diabetology, and pain management. With 388 employees, Medicamen Biotech produces a range of products such as tablets, capsules, syrups, and specialized oncology drugs like Abiraterone acetate and Imatinib mesylate. Medicamen Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medicamen Biotech stock

Net Profit Margin of Medicamen Biotech is 4.88 % in 2026.

Net Profit Margin of Medicamen Biotech changed from 4.37 % to 4.88 %, representing a 11.48% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Medicamen Biotech since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Medicamen Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Medicamen Biotech

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Medicamen Biotech